ProCE Banner Activity

Optimizing Patient Outcomes and Quality of Life With Adjuvant Abemaciclib in HR+/HER2- Early Breast Cancer Through Adverse Event Management

Clinical Thought

Read about how managing the adverse events associated with adjuvant abemaciclib can affect patients with HR-positive/HER2‑negative early breast cancer.

Released: January 31, 2023

Expiration: January 30, 2024

No longer available for credit.

Share

Faculty

Julia LaBarbera

Julia LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Julia LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Los Angeles, California

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: Bio-Theradiagnostics, Cancer Network/MJH Life Sciences.